Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4748 - Responses and Durability of Clinical Benefit in Pancreatic Ductal Adenocarcinoma (PDAC) Patients Treated With Pegilodecakin (AM0010) in Combination With 5-FU/LV and Oxaliplatin (FOLFOX)


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Tumour Site

Pancreatic Adenocarcinoma


J. Randolph Hecht


Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288


J..R. Hecht1, A. Naing2, G.S. Falchook3, M.R. Patel4, R. Aljumaily5, D.J. Wong6, K.A. Autio7, Z.A. Wainberg6, M. Javle8, J. Bendell9, S. Pant10, A. Hung11, M. Oft12, J. Leveque13, K.P. Papadopoulos14

Author affiliations

  • 1 Clinical Medicine, David Geffen School of Medicine at UCLA, 90404 - Santa Monica/US
  • 2 Department Of Investigational Cancer Therapeutics (phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 3 Drug Development, Sarah Cannon Research Institute at HealthONE, 80218 - Denver/US
  • 4 Clinical Trials/drug Development, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota/US
  • 5 Medicine; Secion Of Hematology/oncology, Oklahoma University, Oklahoma City/US
  • 6 Medicine; Division Of Hematology/oncology, David Geffen School of Medicine at UCLA, Santa Monica/US
  • 7 Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 8 Gastrointestinal Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 9 Gi Oncology Research, Sarah Cannon Research Institute/Tennessee Oncology, 37923 - Nashville/US
  • 10 Investigational Cancer Therapeutics; Division Of Cancer Medicine, MD Anderson Cancer Center, Houston/US
  • 11 Biostatistics, ARMO BioSciences, Redwood City/US
  • 12 Pre-clinical And Clinical Development, ARMO BioSciences, Redwood City/US
  • 13 Scientific Affiars, ARMO BioSciences, 94063 - Redwood City/US
  • 14 Clinical research, START Center for Cancer Care, San Antonio/US

Abstract 4748


Therapeutic options for second line metastatic pancreatic ductal adenocarcinoma (PDAC) are limited with FOLFOX or FOLFIRI having mOS of 5-6 months. PDAC has low tumor mutational burden and tumor infiltrating CD8+ T cells are rare, which may explain why immune-oncology approaches to date have been less than promising. Pegilodecakin (AM0010) is a pegylated recombinant human interleukin-10 that stimulates activation, survival and clonal expansion of intra-tumoral, tumor antigen specific CD8+ T cells. Pegilodecakin also up-regulates IFNγ and the expression of MHC, which enables tumor antigen presentation in neoplasias of low mutational burden and promotes immunosurveillance by expanding effector memory T cells (Mumm et al. 2010, 2011). Finally, pegilodecakin reduces tumor inflammatory processes such as angiogenesis and and metastatic dissemination (Oft 2017), the off-target auto-immune side effects of immunotherapy and the inflammatory-related side effects of some chemotherapies, including FOLFOX-induced peripheral neuropathy (Krukowski JNeurosci 2016).


In a 353 patient phase 1/1b dose escalation and expansion study conducted in the US from 2013 to 2017, 21 heavily pretreated metastatic PDAC subjects received pegilodecakin in combination with FOLFOX. Responses were assessed by irRC. CD8 T cell activity was determined by IHC and TCR clonality in the blood.


Table: 1143P

PegilodecakinNPrior TherapiesORRCRDCRmPFSmOSOne- YearTwo- Year
RegimenE (ITT)2Median (Range)(%)(%)(%)(mos)(mos)3OS (%)OS (%)
Plus FOLFOX119 (21)2 (1-5)15.810.573.72.610.242.928.6

Pegilodecakin 5.0 µg/kg + FOLFOX;


E (evaluable - baseline tumor assessment + >1 post-baseline assessments, and no major protocol deviations); ITT (intent to treat); All treated/safety population: n = 25; 25 pts were treated with pegilodecakin (5 ug/kg) in combination with FOLFOX. 21 out of 25 pts progressed on prior gemcitabine containing regimen and did not receive prior platinum containing therapy.


Subjects with OS > 8 mos had 75-250 CD8+ T cells/mm2 in the retreatment tumor and had a clonal expansion of new T cell clones in the blood. Data cut on 05.01.18; Median follow-up 26.4 months (22.0-32.0 months).

Grade 3/4 TrAEs included thromobocytopenia (56%), anemia (44%), neutropenia (36%), leukopenia (12%) and fatigue (12%). Grade 1/2 neuropathy was observed in 16% of patients but no grade 3/4 neuropathy.


Pegilodecakin in combination with FOLFOX is well-tolerated in patients with metastatic PDAC, and has a reduced incidence of FOLFOX related neuropathy. Immune activation and overall survival are encouraging in this advanced PDAC population.

Clinical trial identification


Legal entity responsible for the study

ARMO BioSciences.


ARMO BioSciences.

Editorial Acknowledgement


A. Hung, M. Oft, J. Leveque: Employee: ARMO BioSciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.